Activity of a nitroxylated analog of daunorubicin, ruboxyl, in B-lymphoproliferative disorders

• Published in: Acta haematologica Vol. 105; no. 2; p. 77
• Main Authors: Seminara, P, Franchi, F, Konovalova, N, Pioli, C, Rossetti, R, Tubani, L, Doria, G, Rossi Fanelli, F
• Format: Journal Article
• Language: English
• Published: Switzerland 01.01.2001
• Subjects: Aged; Aged, 80 and over; Animals; Antibiotics, Antineoplastic - administration & dosage; Antibiotics, Antineoplastic - toxicity; B-Lymphocytes - drug effects; B-Lymphocytes - pathology; Cells, Cultured - drug effects; Daunorubicin - administration & dosage; Daunorubicin - analogs & derivatives; Daunorubicin - toxicity; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Humans; Lymphocyte Count; Lymphoproliferative Disorders - complications; Lymphoproliferative Disorders - drug therapy; Male; Mice; Mice, Inbred C57BL; Middle Aged; Multiple Myeloma - complications; Multiple Myeloma - drug therapy; Pilot Projects; Remission Induction; Spleen - cytology; T-Lymphocytes - cytology; T-Lymphocytes - drug effects; Waldenstrom Macroglobulinemia - complications; Waldenstrom Macroglobulinemia - drug therapy
• ISSN: 0001-5792
• DOI: 10.1159/000046538

A nitroxylated analog of daunorubicin, ruboxyl (RBX), showed low toxicity but significant lympholytic effect in preclinical evaluations. A series of studies in vitro and in animals demonstrate that RBX is a putative agent in the treatment of many neoplasms. We report the results of a study in mice in which RBX showed selective B-lymphocyte immunosuppression. On the basis of this experience, RBX was administered to 3 patients with multiple myeloma and two patients with Waldenström's disease. The results of this pilot clinical study show that this compound has good activity and low myelotoxicity and cardiotoxicity, but seems to be characterized by a threatening immunosuppressive effect.